Merck & Company Inc (MRK)vsNephros Inc (NEPH)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
NEPH
Nephros Inc
$4.47
-1.11%
HEALTHCARE · Cap: $44.09M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 321148% more annual revenue ($66.57B vs $20.72M). NEPH leads profitability with a 8.4% profit margin vs 4.8%. NEPH trades at a lower P/E of 25.4x. NEPH earns a higher WallStSmart Score of 58/100 (C).
MRK
Hold36
out of 100
Grade: F
NEPH
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Margin of Safety
+12.6%
Fair Value
$4.62
Current Price
$4.47
$0.15 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Revenue surging 36.2% year-over-year
Earnings expanding 450.0% YoY
Conservative balance sheet, low leverage
Strong operational efficiency at 20.2%
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Moderate valuation
Smaller company, higher risk/reward
ROE of 7.3% — below average capital efficiency
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : NEPH
The strongest argument for NEPH centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 36.2% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : NEPH
The primary concerns for NEPH are P/E Ratio, Market Cap, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while NEPH is a hypergrowth play — different risk/reward profiles.
NEPH carries more volatility with a beta of 1.56 — expect wider price swings.
NEPH is growing revenue faster at 36.2% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
NEPH scores higher overall (58/100 vs 36/100) and 36.2% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Nephros Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Nephros, Inc., a commercial stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company is headquartered in South Orange, New Jersey.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?